Caris Life Sciences, Inc. (CAI)
| Market Cap | 5.69B |
| Revenue (ttm) | 812.03M |
| Net Income (ttm) | -537.96M |
| Shares Out | 282.53M |
| EPS (ttm) | -3.22 |
| PE Ratio | n/a |
| Forward PE | 134.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,832,290 |
| Open | 21.16 |
| Previous Close | 19.24 |
| Day's Range | 19.61 - 21.47 |
| 52-Week Range | 17.15 - 42.50 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 33.67 (+67.18%) |
| Earnings Date | Feb 26, 2026 |
About CAI
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company’s molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising lab... [Read more]
Financial Performance
In 2025, Caris Life Sciences's revenue was $812.03 million, an increase of 96.97% compared to the previous year's $412.26 million. Losses were -$537.96 million, 42.2% more than in 2024.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for CAI stock is "Strong Buy." The 12-month stock price target is $33.67, which is an increase of 67.18% from the latest price.
News
Caris Life Sciences Files Registration Statement for Proposed Initial Public Offering
Caris Life Sciences, a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced...
Caris Life Sciences discloses rise in revenue in US IPO filing
Biotech company Caris Life Sciences filed its paperwork to go public in the U.S. on Friday as the stock market shows signs of recovery after tariff shocks.
Oncology precision medicine platform Caris Life Sciences files for an estimated $300 million IPO
Oncology precision medicine platform Caris Life Sciences files for an estimated $300 million IPO
Caris Life Sciences IPO Registration Document (S-1)
Caris Life Sciences has filed to go public with an IPO on the NASDAQ.